Niagen Bioscience (NAGE) Accounts Payables (2011 - 2026)

Niagen Bioscience (NAGE) has 14 years of Accounts Payables data on file, last reported at $13.3 million in Q1 2026.

• Accounts Payables for Q1 2026 came in at $13.3 million, up 24.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.3 million (up 24.88% YoY), and the FY2025 annual result was $10.8 million, up 26.62% from the prior year.
• Accounts Payables grew to $13.3 million in Q1 2026 per NAGE's latest filing, from $10.8 million in the prior quarter.
• Over five years, Accounts Payables peaked at $13.7 million in Q2 2025 and troughed at $6.9 million in Q3 2024.
• A 5-year average of $10.0 million and a median of $9.8 million in 2022 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2024 and 2025: Accounts Payables fell 24.95% in 2024, then surged 84.59% in 2025.
• A 5-year view of Accounts Payables shows it stood at $9.7 million in 2022, then advanced by 5.71% to $10.2 million in 2023, then declined by 16.67% to $8.5 million in 2024, then grew by 26.62% to $10.8 million in 2025, then increased by 22.98% to $13.3 million in 2026.
• Business Quant data shows NAGE's Accounts Payables at $13.3 million in Q1 2026, $10.8 million in Q4 2025, and $12.7 million in Q3 2025.